FORM	4
------	---

1	Check this box if no
	longer subject to Section
	16. Form 4 or Form 5
	obligations may
	continue. See Instruction
	1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)								•			
1. Name and Address of Reporting Person [*] Taylor Carolyn E.	2. Issuer Name and Ticker or Trading Symbol Tonix Pharmaceuticals Holding Corp. [TNXP]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) C/O TONIX PHARMACEUTICAL CORP., 26 MAIN STREET, SUITE	S HOLDING	3. Date of Earliest Transaction (Month/Day/Year) 05/09/2022						Officer (give title below)Other	r (specify below)	
(Street) CHATHAM, NJ 07928	4	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year	/ /	(Instr. 8)		(A) or Disposed of (D)		(D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	Form:	Beneficial	
		(Month/Day/Year)	Code	v	Amount	(A) or (D)	Price		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in SEC 1474 (9-02) this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(e.g., puts, calls, warrants, options, convertible securities)														
1. Title of	2.	3. Transaction	3A. Deemed	4.		5. Number of	f	6. Date Exercisab	7. Title and Amount of 8. Price		8. Price of	9. Number of	10.	11. Nature	
Derivative	Conversion	Date	Execution Date, if	Transact	ion	Derivative		Expiration Date	Underlying Securities De		Derivative	Derivative	Ownership	of Indirect	
Security	or Exercise	(Month/Day/Year)	any	Code		Securities		(Month/Day/Year	r)	(Instr. 3 and 4) Secur		Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)		Acquired (A)) or	ř í í				(Instr. 5)	Beneficially	Derivative	Ownership
	Derivative					Disposed of	(D)					Owned	Security:	(Instr. 4)	
	Security					(Instr. 3, 4, a	nd						Following	Direct (D)	
						5)					Reported	or Indirect			
				Code	v	(A)		Date Exercisable	Expiration Date		Amount or Number of Shares		Transaction(s) (Instr. 4)	(I) (Instr. 4)	
Stock Option	\$ 0.132	05/09/2022		А		2,131,500		05/09/2023 ⁽¹⁾	05/09/2032	Common Stock	2,131,500	\$ 0 <u>(1)</u>	2,131,500	D	

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Taylor Carolyn E. C/O TONIX PHARMACEUTICALS HOLDING CORP. 26 MAIN STREET, SUITE 101 CHATHAM, NJ 07928	Х							

Signatures

/s/ Jessica Morris as attorney-in-fact	05/11/2022
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.